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Summary
ATM is a PI 3-kinase involved in DNA double-strand break
repair. ATM deficiency leads to ataxia-telangiectasia (A-T),
a syndrome of cancer susceptibility, hypersensitivity to
ionizing radiation, immune deficiency, and sterility [1, 2]—
phenotypes that can straightforwardly be attributed to
a defective response to DNA damage. Yet patients with A-T
also suffer from ataxia, speech defects, and abnormal body
movements [3–5]—neurological phenotypes whose origins
remain largely unexplained. Compounding the discordance,
Atm mutations in mouse interfere with DNA repair but have
only mild neurological symptoms [6–9], suggesting that
the link between DNA damage and the death of neurons
can be broken [10–12]. We find that in neurons, ATM protein
has a substantial cytoplasmic distribution. We show that in
Atmtm1Awb mice, hippocampal long-term potentiation is
significantly reduced, as is the rate of spontaneous vesicular
dye release, suggesting a functional importance of cyto-
plasmic ATM. In the cytoplasm, ATM forms a complex with
two synaptic vesicle proteins, VAMP2 and synapsin-I, both
of which must be phosphorylated to bind ATM. Also, cyto-
plasmic ATM physically associates with the homologous
PI 3-kinase, ATR. The neurological symptoms of ataxia-
telangiectasia may thus result from defective nonnuclear
functions of ATM not associated with DNA repair.Results
ATM Distributes in Neuronal Cytoplasm and Fails
to Respond to DNA Damage
ATM is best known for its critical role in the DNA damage
response where, after autophosphorylation on serine 1981
(S1981), the ATM dimer dissociates into two catalytically
active monomers [13]. Although ATM is a predominantly
nuclear protein, studies have shown significant amounts of
cytoplasmic ATM protein in neurons, the function of which
has not been completely identified [14–18]. We performed
subcellular fractionations of tissue extracts from mouse brain,
spleen, and thymus (Figure 1A). All three tissues had nuclear
ATM (lanes 4–6), whereas in spleen and thymus, cytoplasmic
ATM was nearly undetectable (lanes 2 and 3). By contrast, in
brain tissue, cultured neurons, or N2a cells (Figure 1C, lanes
1 and 2), significant quantities of cytoplasmic ATM were
present. Antibody specificity was confirmed by the absence
of a band in Atmtm1Awb tissues (see Figure S1C available
online). Immunohistochemistry of cryostat sections (Figures
1Ba and 1Bb; Figures S1A and S2B) and of cultured cells*Correspondence: herrup@biology.rutgers.edu(Figures 1Dd and 1De) was consistent with these findings.
A similar nuclear/cytoplasmic distribution was found with a
GFP-ATM fusion protein, transiently expressed in either
cortical neurons (Figure 1Da) or N2a cells (Figure 1Db). Non-
neuronal cells such as NIH 3T3 and HeLa had predominately
nuclear ATM (Figure 1C, lanes 3 and 4; Figure 1Dc). Further,
in NIH 3T3 cells (Figure 1Df), GFP-ATM was overwhelmingly
nuclear. Finally, ATM could be found in association with
synaptic vesicles and synaptic membranes in synaptosomal
fractions from mouse brain (Figure 1E). Thus, four independent
lines of evidence support the existence of neuronal cyto-
plasmic ATM.
The neuron-specific occurrence of cytoplasmic ATM
suggests a function distinct from its role in the DNA damage
response. If primary neuronal cultures are exposed to 5 Gy
of radiation, the phospho-S1981-ATM epitope appears in the
nuclei of neurons or N2a cells as reported previously [19],
but not in the cytoplasm (Figure 1F). These results were veri-
fied with etoposide (Figure 1G; Figure S2) and in vivo with
ionizing radiation (Figure S3A). ATM activation in the nucleus
was demonstrated by the enhanced phosphorylation of two
ATM targets, p53 and Chk2 (Figure S3B). Thus, neither irradia-
tion nor topoisomerase inhibitors activate cytoplasmic ATM,
suggesting that its function is unrelated to the DNA damage
response.
ATM Deficiency Causes Dysfunction of Synaptic Vesicle
Cycling and Long-Term Potentiation
The cytoplasmic and/or synaptosomal presence of ATM in
neurons prompted us to ask whether ATM might play a role
in synaptic function. We recorded from in vitro slices of adult
wild-type and Atmtm1Awb hippocampus but found no deficit
in baseline synaptic transmission. Both genotypes had similar
input-output curves (Figure 2A), although there was a tendency
for the mutants to show a plateau in responsiveness at lower
stimulus currents than wild-type mice. We next tested the
consequences of ATM deficiency on long-term potentiation
(LTP) at the Schaffer collateral-CA1 synapse. Examination of
theta burst stimulation (TBS)-induced LTP revealed that
Atmtm1Awb mice have a considerable deficit as compared to
wild-type animals (Figure 2B). In control mice, TBS produced
a maintained elevation in synaptic strength; the same stimula-
tion protocol produced only a modest long-term increase in
Atmtm1Awb mice (Figure 2B). Previous studies indicate a defect
in exocytosis in lymphocytes of ataxia-telangiectasia (A-T)
patients [20]. This led us to question whether a defect in vesicle
recycling might occur in Atm mutant neurons. We monitored
FM4-64 dye uptake and release from cultured neurons derived
from either wild-type or Atmtm1Awb mice. There was no signif-
icant difference in FM4-64 dye uptake between Atmtm1Awb and
wild-type neurons or wild-type neurons treated with RNA inter-
ference (RNAi) (data not shown). By contrast, spontaneous
dye release was significantly slower in Atmtm1Awb and Atm
small interfering RNA (siRNA)-treated cultures than in wild-
type, untreated dishes (Figure 2C; Movies S1–S3). Thus, in
the absence of ATM, spontaneous vesicle release is reduced
in culture, and the ability to establish and maintain LTP is
significantly impaired.
Figure 1. ATM Distributes in Neuronal Cytoplasm
and Does Not Respond to DNA Damage
(A) Cytoplasmic and nuclear protein extracts
from adult mouse brain (Br), spleen (Sp), and
thymus (Th) were blotted with ATM antibody.
Hsp90 and HDAC-1 were used as cytoplasmic
and nuclear markers, respectively.
(Ba and Bb) ATM immunostaining was performed
on 10 mm cryostat sections from adult mouse
cerebellum (Ba) and cortex (Bb). The inset
illustrates the presence of immunoreactivity in
Purkinje cell cytoplasm (black arrow) as well as
nucleus (brown arrow), with weak staining in the
primary dendrite (white arrow).
(C) Cytoplasmic extracts from cultured neurons
and N2a cells contain ATM; NIH 3T3 and HeLa
cell cytoplasm was immunonegative.
(Da–Df) ATM immunostaining (Dd–Df) and GFP-
ATM deployment (Da–Dc) are found in the cyto-
plasm of cultured neurons (Da and Dd) and N2a
cells (Db and De), but not of NIH 3T3 cells (Dc
and Df).
(E) ATM in mouse brain synaptosomes. Crude
synaptosomes were fractionated into presyn-
aptic cytosol (Cyt), synaptosome plasma mem-
brane (PM), and synaptic vesicle (SV) fractions.
Subcellular distribution of ATM was identified
with specific fraction markers.
(F) Activation of ATM occurs only in the nucleus.
Cytoplasmic (cyto) and nuclear (nucl) extracts
from cultured neurons (top) and N2a cells
(bottom) 1 hr after exposure to 5 Gy of gamma
radiation (‘‘IR+’’). Untreated samples are denoted
‘‘IR2’’. Lysates were blotted with a phospho-
S1981-ATM.
(G) Immunofluorescence images of activated
ATM (phospho-S1981) show exclusively nuclear
localization. Cultured neurons were treated with
etoposide.
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We sought to determine the mechanistic basis of these func-
tional deficits. Recently, hundreds of potential ATM/ATR
targets have been identified [21]. In light of our findings, two
proteins from this list seemed especially noteworthy: VAMP2
and synapsin-I. Both are vesicle proteins that are involved in
vesicle trafficking and release. VAMP2 (synaptobrevin) forms
a central part of the soluble NSF attachment protein receptor
(SNARE) complex that mediates synaptic vesicle fusion with
the cell membrane during neurotransmitter release. By immu-
nocytochemistry, ATM partially colocalized with VAMP2
in cultured neurons (Figure 3A). This association was con-
firmed by coimmunoprecipitation with antibody to either
ATM or VAMP2 from protein extracts of adult mouse brain
(Figure 3B). Having demonstrated the physical association of
VAMP2 and ATM, we immunoprecipitated VAMP2 from cyto-
plasmic fractions of mouse neocortex and cerebellum and
examined the precipitates on western blots with an antibody
against [S/T]Q-phosphorylated sites—the canonical ATM/
ATR target sequence. A strong band of staining was found
(Figure 3C). The amino acid sequence of VAMP2 revealed
two potential ATM/ATR phosphorylation sites: T35 and S75.
We constructed nonphosphorylatable alanine substitution
mutants at these sites and expressed them as FLAG-tagged
derivatives in N2a cells, which we then differentiated with dibu-
tyryl-cAMP. Blots of FLAG immunoprecipitates probed with
either phospho-[S/T]Q or a specific phospho-T35-VAMP2antibody (P-T35) revealed that T35 is significantly phosphory-
lated in normal neuroblastoma cells (Figure 3D). We observed
that blocking T35-VAMP2 phosphorylation had two significant
consequences. First, immunoprecipitation with ATM antibody
revealed that ATM does not bind to the T35A-VAMP2 mutant,
suggesting that ATM binds primarily to the phosphorylated
form of VAMP2 (Figure 3D). Second, overexpression of the
T35A-VAMP2 mutant, but not the S75A mutant or wild-type
VAMP2, in N2a cells was associated with a decrease in the
rate of FM4-64 dye release from differentiated N2a cells
(Figure S4). Thus, phosphorylation of VAMP2 at T35 induces
ATM binding and leads to a change in neuronal function.
Synapsin-I is an abundant neuronal phosphoprotein that is
associated with synaptic vesicles [22]. Synapsin-I/ATM coim-
munoprecipitations revealed that they are physically associ-
ated (Figure 3E). To identify the synapsin-I kinase, we immuno-
precipitated synapsin-I from wild-type or Atmtm1Awb brain and
probed with the [S/T]Q antibody (Figure 3F). In the mutant,
immunoreactivity for the [S/T]Q antibody was reduced to
nearly undetectable levels. Similar results were found in
primary cultures after Atm siRNA introduction (Figure 4A).
Serine 656 of synapsin-I is a strong theoretical candidate for
an ATM/ATR phosphorylation target, a prediction we con-
firmed by site-directed mutagenesis. Furthermore, the non-
phosphorylatable S656A synapsin-I mutant could no longer
pull down ATM as efficiently as wild-type (Figure 3G). As with
VAMP2, blocking synapsin-I phosphorylation had significant
functional consequences. Normally, synapsin-I and ATM
Figure 2. Long-Term Potentiation and Synaptic Vesicle Recycling Are
Defective in Atm-Deficient Brains
(A) Input-output relations showing that baseline transmission was not signif-
icantly different between wild-type and Atmtm1Awb mice.
(B) Schaffer collateral long-term potentiation (LTP) is dramatically reduced
inAtmtm1Awb mice. The time course of LTP elicited by theta burst stimulation
(TBS) shows the expected increase in the field excitatory postsynaptic
potential (fEPSP) slope (156% 6 8.1% measured at 175–180 min after
TBS stimulation, n = 12) in wild-type slices, but not in slices from Atmtm1Awb
mice (113%6 5%, n = 6; p < 0.01). Inset: sample fEPSPs from wild-type (WT)
and Atmtm1Awb (KO) recordings illustrating the different responses to TBS
stimulation.
(C) FM4-64 dye release kinetics is less rapid in Atm-deficient cells. In
cultures that lack ATM (small interfering RNA [siRNA], green; Atmtm1Awb,
red), spontaneous release kinetics are slowed compared to wild-type
(blue). Whereas 60% of the FM4-64 dye is lost after 25 min from wild-type
cells, siRNA-treated or Atmtm1Awb neurons lose only 30% of their dye in
the same period of time (n = 6, p < 0.01). Graphs represent averages of
three independent experiments. Error bars represent standard deviation
(SD).
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found in a punctate pattern along the neurites (Figure 3H). In
addition to inhibition of ATM binding, the subcellular distribu-
tion of both synapsin-I and ATM was altered when S656 phos-
phorylation was blocked. Coexpression of an mCherry-tagged
wild-type synapsin-I with GFP-tagged ATM showed a numberof puncta where the two proteins colocalized (Figure S5).
By contrast, when synapsin-I carries the S656A mutation, the
colocalization with ATM is reduced.
Cytoplasmic ATM and ATR Physically Link VAMP2
and Synapsin-I
Having identified ATM as the source of S656 synapsin-I phos-
phorylation, we next sought to determine the identity of the
VAMP2 kinase. Proteins were immunoprecipitated from
primary cortical neurons that had been treated with ATM
siRNA. Whereas synapsin-I [S/T]Q reactivity was largely
blocked by ATM knockdown, [S/T]Q staining of VAMP2 was
only slightly reduced (Figure 4B). A similar result was found
when VAMP2 was immunoprecipitated from Atmtm1Awb brain
(Figure 3G). Thus, it is unlikely that ATM is a major VAMP2
kinase. We next asked whether ATR, a closely related member
of the PI 3-kinase family, might be involved. Application of Atr
RNAi all but eliminated the phospho-[S/T]Q and phospho-T35
reactivity of VAMP2 immunoprecipitates and immunostaining
of primary neurons (Figures 4B and 4C; Figures S6 and S7A),
pointing to ATR as the predominant VAMP2 PI 3-kinase. There
would thus appear to be a reciprocal relationship among the
four proteins, with VAMP2 relying on ATR and synapsin-I
relying on ATM as a PI 3-kinase.
Its participation in the phosphorylation of VAMP2 suggested
that ATR might also be a VAMP2 binding partner. Immunos-
taining of brain tissue or cultured neurons demonstrated that
ATR has a significant cytoplasmic distribution (Figures 4Da–
4Dc); the distribution of exogenous GFP-ATR suggested
a similar conclusion (Figure 4Dd). Further, synaptosomal
preparations contained ATR in the same fractions as ATM
(Figure 1E). ATR physically associates with VAMP2 and synap-
sin-I, because antibodies to ATR pulled down both synaptic
proteins. Reverse immunoprecipitations were also successful
(Figure 4E). These multiple interactions led us to ask whether
all of the proteins coexisted in a single complex. VAMP2 can
immunoprecipitate synapsin-I from synaptosomal prepara-
tions of cultured cortical neurons, and the reverse immuno-
precipitation confirmed the synapsin-I/VAMP2 association
(Figure 4F). Yet when Atm siRNA was used to block the
synthesis of ATM in the cultured neurons, VAMP2 and synap-
sin-I failed to immunoprecipitate each other (Figure 4F;
Figure S7B). This is strong evidence that ATM acts as a phys-
ical link between VAMP2 and synapsin-I. We next asked
whether ATM and ATR were associated with each other. We
coexpressed ATM and ATR, each with a different epitope
tag, in N2a cells. We performed immunoprecipitations with
one of the epitope tags and did western blots with an antibody
to the other epitope as probe. A strong band of staining was
found in cytoplasmic but not nuclear fractions (Figure S8).
Reversing the epitope tags produced a similar result. This
suggests that the ATM and ATR proteins do indeed interact,
but that their physical association in neurons occurs primarily
in the cytoplasm.
Discussion
Neurons and neuronal cell lines appear to be unique in that
a substantial fraction of their ATM protein is cytoplasmic,
a conclusion supported by three different lines of evidence:
subcellular fractionation, immunocytochemistry, and the
distribution of an exogenous GFP-ATM fusion protein. The
prominence of this cytoplasmic component is cell type
specific, because neither spleen, thymus, nor cell lines of
Figure 3. VAMP2 and Synapsin-I Are Novel Cyto-
plasmic Partners of ATM in Neurons
(A) VAMP2 and cytoplasmic ATM colocaliza-
tion. Cultured cortical neurons were stained
with antibodies against ATM (green) or VAMP2
(red).
(B) VAMP2 physically interacts with cytoplasmic
ATM in mouse brain. Immunoprecipitations of
cytoplasmic (cyto) and nuclear (nucl) extracts
from 4- to 6-week-old mouse brain were probed
with the antibodies indicated.
(C) Neuronal VAMP2 immunoprecipitation is
labeled with phospho-[S/T]Q antibody.
(D) VAMP2 Thr35 is phosphorylated in N2a cells,
which is necessary for binding to ATM. The T35A
and T35A/S75A alanine-substitution mutants
lose virtually all of their phospho-T35 (P-T35)
signal (second row), their phospho-[S/T]Q signal
(third row), and their ability to immunoprecipitate
ATM (first row).
(E) Synapsin-I and ATM are physically associ-
ated. Synaptosomal protein extracts from adult
mouse brain were immunoprecipitated and
blotted with ATM synapsin-I or VAMP2 anti-
bodies.
(F) Synapsin-I, but not VAMP2, is an enzymatic
target of ATM. Cytoplasmic protein extracts
from wild-type (+/+) or Atmtm1Awb (2/2) mouse
brain were immunoprecipitated with either syn-
apsin-I (top) or VAMP2 (bottom) and blotted
with [S/T]Q antibody.
(G) S656 is critical for ATM binding. Myc-tagged
wild-type and S656A synapsin-I were overexpressed in N2a cells, immunoprecipitated with anti-myc antibody, and blotted with anti-ATM or anti-[S/T]Q.
(H) ATM and synapsin-I have unique but overlapping distributions in primary neuronal cultures.
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their nucleus.
We postulate that this nonnuclear ATM is different in its
function as well as in its location. The biochemical and physicalrelationships among ATM, ATR, VAMP2, and synapsin-I,
coupled with the defects in LTP and spontaneous dye release
observed in ATM-deficient neurons, are strong evidence that
cytoplasmic ATM plays cellular roles in neurons that areFigure 4. ATM and ATR Link VAMP2 and Synapsin-I
(A–C) ATR phosphorylates synapsin-I. Cortical cultures were
transfected with the siRNA species indicated. Immunopre-
cipitation from cytoplasmic extracts was performed with
either anti-synapsin-I (A) or anti-VAMP2 (B and C) and
blotted with anti-phospho-[S/T]Q (A and B) or a phospho-
T35-specific antibody (C). ATM knockdown reduces the syn-
apsin-I phosphorylation, whereas Atr knockdown reduces
VAMP2 phosphorylation, specifically on T35.
(Da–Dd) ATR is found in neuronal cytoplasm.
(Da) ATR immunostaining of mouse cerebellar sections.
(Db and Dd) Immunostaining of endogenous ATR (Db) and
localization of exogenous GFP-ATR (Dd) in cultured neurons.
(Dc) Subcellular ATR distribution in cultured cortical
neurons.
(E) Cytoplasmic ATR in neurons partially colocalizes with
synapsin-I and VAMP2. Immunoprecipitation of ATR pulls
down both synapsin-I (top left) and VAMP2 (top right). The
reverse immunoprecipitations are also effective.
(F) ATM forms a link between synapsin-I and VAMP2. Intro-
duction of siRNA to Atm disrupts association of VAMP2
with synapsin-I in immunoprecipitations.
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2095unrelated to the DNA damage response. Cytoplasmic ATM
shows no evidence of activation as assessed by phosphoryla-
tion at S1981. Yet others have speculated that ATM kinase
activity unrelated to the phosphorylation of S1981 exists [23,
24], and the ATM-dependent phosphorylation of synapsin-I
at S656 would tend to support this suggestion.
Both VAMP2 and synapsin-I are best known for their roles in
the presynaptic nerve terminal, and we have shown that ATM
protein is found in synaptosomal preparations. It is unlikely,
however, that the function of cytoplasmic ATM is restricted
to presynaptic terminals, because immunocytochemistry
also reveals robust staining in the cell soma and dendrites.
The actions of cytoplasmic ATM and ATR appear to be
symmetrical. We show that all four proteins can physically
associate with one another in the cytoplasm, but, whereas
the ATM kinase targets synapsin-I, ATR targets VAMP2. The
involvement of the ATR kinase in the cytoplasmic function of
ATM is intriguing, because a partial deficiency of ATR leads
to devastating neurological consequences [25].
The subtle nature of the synaptic changes in ATM-deficient
neurons suggests a regulatory role for cytoplasmic ATM in
neuronal activity rather than a central function in synaptic
connectivity. It seems likely that either phosphorylation of
VAMP2 or its binding to ATM would sterically interfere with its
normal function in vesicle docking and fusion. Perhaps ATM
holds a pool of VAMP2 and/or synapsin-I in reserve to be
released as needed. Alternatively, ATM may assist in the trans-
port of VAMP2 and synapsin-I by keeping them in a protected
state, consistent with the distribution of the nonphosphorylat-
able proteins in cultured neurons.
In the aggregate, these novel associations of ATM with
synaptic function provide new and unexpected explanations
for the severe neurological symptoms in children with A-T
and possibly open new avenues of intervention specifically
related to cytoplasmic ATM function [26]. It would appear
that in conjunction with the cell-cycle-related cell death [27],
A-T neurons are subject to a synaptic dystrophy that can
only exacerbate the damage caused by cell loss.
Experimental Procedures
Introduction of siRNA in Primary Cultural Neurons
siRNA duplexes against mouse Atm and Atr were purchased from Inte-
grated DNA Technologies. We used mainly siRNA in our study; the Atm
sense strand was 50-GGAGCAUGCUCUAAGGACATT-30, and the Atr sense
strand was 50-CUCCAAAGCACCACUGAAUTT-30. Primary cultures of
mouse embryonic neurons were transfected with siRNA plus Lipofectamine
2000, first at 5 days in vitro (DIV) and again at 9 DIV. Samples were mainly
collected between 10 and 14 DIV.
FM4-64-Tracking Vesicle Recycling
Dissociated cortical neurons were cultured in vitro for 14 days and then
incubated in 10 mM FM4-64 (Molecular Probes). Dye uptake was induced
by exposing the neurons to Tyrode’s solution containing 47 mM KCl and
2 mM CaCl2 for 90 s at room temperature. Fluorescence images of FM4-
64-labeled vesicles were captured after 15 min of perfusion with dye-free
solution. For live imaging, one frame was captured every 10 s over a total
analysis period of 1 hr.
Field Potential Recording
Extracellular recordings of field excitatory postsynaptic potentials (fEPSPs)
were made with artificial cerebrospinal fluid (ACSF)-filled glass electrodes
(5–10 mm tip diameter). Test stimuli (0.1 ms) were delivered with a bipolar
platinum/iridium stimulating electrode at 1 min intervals, except for special-
ized protocols that elicited changes in synaptic strength (see below). For
recordings of CA1 activation by Schaffer collateral stimulation, recording
and stimulating electrodes were both placed in stratum radiatum. Each
experiment was begun by obtaining input-output relationships to establishthe strength of baseline synaptic transmission. A Grass S8800 stimulator
connected to a Grass PSIU6 photoelectric stimulus isolation unit was
used to deliver a series of increasing-intensity constant-current pulses.
Current magnitude was adjusted to elicit responses ranging from just
suprathreshold to near maximal. Following this, stimulus intensity was
adjusted to evoke fEPSPs 30%–40% of maximum, typically 30–40 mA. To
elicit LTP, TBS was used. A single TBS consisted of 12 bursts of four
100 Hz pulses spaced 200 ms apart. Response magnitude was quantified
with the slope of the field potential.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures, four
figures, and three movies and can be found online at http://www.cell.
com/current-biology/supplemental/S0960-9822(09)01896-X.
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